Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1804 results
November 2016
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deathsEntresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]…
-
Media ReleaseNovartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosisPriority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also…
-
Media ReleaseNovartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported painCosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high…
-
Media ReleaseNovartis improves ranking in 2016 Access to Medicine IndexNovartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income…
-
In The NewsThe price of drugs should reflect the value they deliverIn Forbes commentary, Novartis CEO says industry should focus on outcomes for patients and healthcare systems.
-
Featured NewsWhen innovation draws a new future for patient treatments
A recent summit explored how technological advances could impact patient care.
-
Featured NewsNovartis, Medikidz® and the COPD Foundation: a partnership of superhero proportions
We teamed up with Medikidz and the COPD Foundation to develop a creative way to explain COPD to children.
-
Media ReleaseNovartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancerPriority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…
October 2016
-
Experimental treatment clears malaria infections in small clinical study
Compound offers a potential tool for fighting drug-resistant malaria parasites.
-
Media ReleaseNovartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology ProductBasel, October 31, 2016 - Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "…
-
Featured NewsNovartis dialogue to explore solutions to the rise of chronic diseases in the developing world
The event, called “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016, on the Novartis Campus in Basel, Switzerland and will also be webcast.
-
Media ReleaseNovartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbustersQ3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301…
Pagination
- ‹ Previous page
- 1
- …
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- …
- 151
- › Next page